NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00154362
A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 19
- Registration Number
- NCT00154258
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1677
- Registration Number
- NCT00154271
Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 196
- Registration Number
- NCT00149968
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 246
- Registration Number
- NCT00149929
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2010-09-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 832
- Registration Number
- NCT00149851
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 77
- Registration Number
- NCT00149890
- Locations
- 🇩🇪
Novartis Investigational Site, Various Cities, Germany
Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion
Phase 4
Terminated
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-02-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00150085
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 264
- Registration Number
- NCT00149864
Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 23
- Registration Number
- NCT00149942
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
© Copyright 2024. All Rights Reserved by MedPath